Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Melaleuca quinquenervia pollen is an allergenic extract derived from the pollen of the Melaleuca quinquenervia tree, also known as the paperbark or niaouli tree. [22, 24] It is used for the diagnosis of allergies through skin prick or intradermal tests and for treatment via allergen-specific immunotherapy (also known as hyposensitization). [19, 20, 33] The diagnostic use relies on the extract's ability to trigger a localized IgE-mediated histamine release in sensitized individuals, resulting in a wheal-and-flare reaction. [19] For therapeutic purposes, gradually increasing doses of the extract are administered subcutaneously to modulate the immune system, induce tolerance, and reduce the symptoms of allergic rhinitis upon subsequent environmental exposure. [19, 20] While the pollen is a known allergen, its clinical significance as a primary cause of respiratory allergies is debated, as the tree is primarily insect-pollinated, meaning its pollen is heavy and not easily dispersed by wind. [30, 34] Some positive allergy tests may result from cross-reactivity with other common aeroallergens, such as Bahia grass pollen. [30, 31]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Melaleuca quinquenervia pollen.